Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-321 (ripasudil) in Fuchs endothelial corneal dystrophy after descemetorhexis
2019-003280-22Phase 2Completed
- Sponsor
- Kowa Research Institute, Inc.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Fuchs endothelial dystrophy (FED) comparing K-321 (ripasudil) with Placebo (2 arms). Primary endpoint: Central corneal endothelial cell density at Week 12. Started Feb 2020; status: completed.
02
Drugs
ripasudil
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on 2019-003280-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003280-22.